If you are the investors looking for the business development of Drug Discovery and Development in China, IDDST 2008 provides you perfect face2face opportunities through such overload innovators' presentations and so much breakthrough showcases for your choose. You can not only go through the detail scientific and technological findings by those innovators' descriptions, and report on the projects they are making progress in, you can also learn the infrastructure of investment of drug discovery projects in China through the roundtable discussions as the following:
1) China Drug Discovery Roadmap - Where is the New DD Venture Frontier
2) Why Invest in China for your drug discovery programs?
3) Who is Actively Investing & in What kind of drug discovery capacity in China ?
4) How to Form Joint venture business with Chinese Government owned bio/pharmaceutical companies?
5) What are the hottest Drug R & D opportunities in China today and over the next 2-5 years ?
6) Understanding How to be successful in drug discovery in China
7) How to Build a Global IP Portfolio in China based Drug Discovery Company;
8) Recent Success Stories and a Trend to the Future.
9) Roles of Scholars and entrepreneurs in Drug Discovery in China
10) Will the technologies come from Academic Sources or from Academic Collaborations in China be commercialized globally?
11) What's proprietary in the China academic Drug Innovation Institutions?
12) How should it be commercialized, and by whom?
13) Who owns the I.P. and how should it be commercialized?
14) What are the tax implications for investing in China for non-China investors in Drug Discovery?
15) Will Strategies in M & A (Mergers & Acquisitions) apply for New Therapeutic Innovators in China ? and What will happen on the cross-border M&A scene in general over the next 2-5 years?
16) What Role will China Pharma & Biotech Companies Play ?
17) Who will lead the Merging and Acquisition trend?
18) What is the better strategy in M & A, based upon domestic partners or set footprint overseas?
19) What Bio or Pharma Theraepeutic Business Models suitable for setting up across cultural New Drug Searching company in China
20) Will China and its investors & NEC-entrepreneurs innovate and lead the way? Or will they merely be fast followers of foreign business and investing innovations?
21) How to Gain the Insight into the Investment Security in China ?
22) Reducing Costs and Risk in Drug Discovery Entrepreneurs;
23) How to enter into Early Stage investment ?
24) Should Foreign Investors Seek Public Exits or Liquidity Events on Chinese Exchanges such as Hong Kong 's Hang Seng ? or direct go to IPO on NSDQ
26) What regulations need to change for this to happen?
27) Which Investors will lead the way?
28) The Successful Case Studies from Recent winners in Drug Innovations
29) How to define Value-added Pharmaceutical Outsourcing?
30) How to Add the Most Value in the Out-sourcing Equation in Biotech/Pharmaceutical Drug Discovery?
31) Where is the government heading in terms of allowing off-shore structures?
32) How to meet the challenges in high turnover of employees in CRO and CMO Business?
33) Current Trends in Seed & Early Stage Investing in Drug Discovery in China
34) Licensing Issues from Research Institutes and Universities?
35) How to translate overseas IP into business operations?
If you are interested in joining us for above mentioned topics or you want to lead a panel, please contact us. We won't let you down. You will deem to receive respect and find the there are so much room to explore by you in such a fast growing drug Discovery R & D transfer to China.
Contact us Now!
Emily Liu
Project Leader
The Organizing Committee of IDDST 2008
BIT Life Sciences
26 Gaoneng St . , F4
Dalian Hightech Zone
Dalian, LN 116025, China
Tel: 0086-411-84799609x810
Fax: 0086-0411-84799629
Email: emily@iddst.com
Kelly Wang
CEO of BIT Life Sciences, Inc.
26 Gaoneng St . , F4
Dalian Hightech Zone
Dalian , LN 116025, China
Tel: 0086-411-84799609x810
Fax: 0086-0411-84799629
Email: kelly@iddst.com
|
